6194-006

Systemic Lupus Erythematosus Research Trial – (106 Weeks)


Age: 18+



Participating Locations

COUNTRY
country-icon
Chile

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: July 16, 2024

Official Title

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus

ClinicalTrials.gov ID

NCT06161116

Sponsor

Merck Sharp & Dohme LLC

Study Description

  • Brief Summary:

    The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypothesis is that at least 1 of the MK-6194 arms is superior to placebo in the primary endpoint of percentage of participants with systemic lupus erythematosus responder index (SRI-4) response at Week 28.

  • Condition or Disease:

    Systemic Lupus Erythematosus

  • Intervention/Treatment:

    Biological: MK-6194 Biological: MK-6194 Biological: Placebo Biological: MK-6194,Biological: Placebo Biological: MK-6194,Biological: Placebo
  • Phase:

    PHASE2

  • Ages Eligible for Study:

    18 Years and 75 Years (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Systemic Lupus Erythematosus

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content